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Abstract 
Background: Drug-eluting stents (DES) reduce stent restenosis compared with bare-
metal stents (BMS). However, their use in patients requiring long-term oral 
anticoagulation (OAC) is controversial owing to increased risk of bleeding associated 
with OAC plus antiplatelet treatment over time.  
Objective: To assess the safety of DES vs BMS in patients requiring long-term OAC 
for any reason. 
Methods: Prospective observational multicenter study conducted at 6 teaching centers 
of patients undergoing percutaneous coronary intervention who required OAC for any 
reason. Adverse outcomes were analyzed at 1 year of follow-up.  
Results: We identified 1,002 patients requiring OAC (mean age: 72 years, male 72%). 
Six- hundred and thirteen patients (61.2%) received BMS and 389 (38.8%) DES. 
Diabetes, previous PCI, myocardial infarction and acute coronary syndrome at 
admission (P<0.0001) were more common in patients with DES. Antithrombotic 
prescribing was similar at discharge between groups (TT: 51.5% vs 50.9%, clopidogrel 
plus OAC: 7.0% vs 5.0% and DAPT: 41.4% vs 42.7%, p=0.52). DES and BMS patients 
showed similar rates of total bleeding (15.2% vs 13.4%, adjusted HR 0.82 [0.58-1.17, 
p=0.82 and major bleeding (6.2% vs 6.0%; adjusted HR 1.22 [0.71-2.09], p=0.46) and 
MACE (15.2% vs 18.6%, adjusted HR: 0.82 [0.57-1.17], p=0.28, while restenosis was 
lower in patients with DES (5.3% vs 8.5%, adjusted HR. (0.52 [0.29-0.92], p=0.02. Cox 
analysis after propensity score selection of 368 matched pairs demonstrated that DES 
use was not associated with a higher incidence of total bleeding or major bleeding. 
Conclusion: DES use is safe in patients with an indication for long-term OAC. 
Word count: 249.  
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Highlights 
 DES use is safe in patients with an indication for long-term OAC. 
 DES and BMS patients showed similar rates of major bleeding and MACE. 
 Restenosis rate was lower in patients with DES compared to those with BMS. 
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INTRODUCTION 
 Many patients with cardiovascular disease require antithrombotic therapy with 
oral anticoagulation (OAC) in combined with platelet function inhibition. Typical 
indications for OAC are AF, mechanical valve prosthesis, mitral stenosis, stroke, deep 
venous thrombosis, pulmonary embolism and hematological disorders with a 
thrombotic tendency[1-5].
 
Between 5-10% of patients undergoing percutaneous 
coronary stent implantation (PCI-S) are on OAC at the time of stenting and the 
combination of OAC with a single antiplatelet (DAT) or with dual antiplatelet therapy 
(triple therapy: TT)[1] is usually recommended for these patients despite the associated 
bleeding risk[1,2,6].  
 DES reduces the rate of target vessel restenosis (TVR) compared with 
BMS[7,8]. Historically, their higher cost and requirement for extended duration of 
DAPT had restricted their use to patients at higher risk of restenosis (such as those with 
total occlusions, in-stent restenosis, and/or diabetes mellitus)[6,9]. Current 
AHA/ACC/HRS guidelines recommend avoiding DES use at the time of PCI-S in 
patients requiring long-term OAC owing to the increased risk of bleeding associated 
with prolonged TT[2] and since premature interruption of DAPT may result in a higher 
incidence of early and late stent thrombosis[1,2,6, 7-10]. Although current US 
guidelines recommend avoiding DES in patients who are at high risk of bleeding, 
updated European guidelines indicate that second generation DES should be the default 
choice in those patients, [1,2]  coupled with shorter duration DAPT[1]. More recently, 
guidelines on myocardial revascularization recommend to use DES in any PCI, 
irrespective of concomitant anticoagulant therapy [6].  These discrepancies exist as a 
result of conflicting evidence concerning the optimal choice of stent in patients 
requiring chronic OAC. Some studies have reported that DES use was associated with a 
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reduction in TVR but increased risk of bleeding, while others found no difference in the 
frequency of bleeding events[13-17].  
The aim of the present study was to compare the safety of DES and BMS in a large 
prospective multicenter cohort of “real-world” patients requiring long-term OAC for 
any reason. 
 
METHODS 
Study population and design 
 We analyzed a prospective cohort study of 1,002 consecutive patients 
undergoing PCI-S who required OAC for any reason. The population consisted of two 
distinct prospective cohorts: (A) patients enrolled between January 2003 and June 2006 
at six Spanish teaching hospitals and one in the United Kingdom (405 patients, 
40.4%)[16] (B) patients enrolled between 2007 and 2014 at a single Spanish teaching 
hospital (597 patients, 59.5%).  
 Patients with a pre-existing diagnosis of permanent, persistent or paroxysmal AF 
and those who developed new-onset AF during their index admission were included in 
this analysis, as well as patients with any other indication for OAC (previous stroke, 
mechanical heart valve, venous thrombosis or pulmonary embolism). The risk of stroke 
or systemic embolism in AF patients was assessed using the CHA2DS2-VASc score[1,2] 
and bleeding risk estimated using the HAS-BLED score[1,2]. 
 
Choice and duration of antithrombotic therapy at discharge 
 Since this was an observational study, decisions concerning the intervention 
strategy, type of stent used, and the choice and duration of discharge antithrombotic 
therapies were left at the discretion of the attending Cardiologist. The exact duration of 
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chosen treatment was recorded in all patients.  Consistent with ESC guideline 
recommendations, DAPT (aspirin 100 mg once a day and clopidogrel 75 mg once a 
day) was continued for at least 1 month following PCI with BMS and 3-12 months 
following PCI with DES, with use of a single antiplatelet agent until at least complete 
12 months. Patients treated with OAC received vitamin K antagonists or non-VKA oral 
anticoagulants (DOACs, ie. Dabigatran 110 mg/b.id., rivaroxaban 15 mg/per day or 
apixaban 5 mg/bid) plus DAPT, or vitamin K antagonists (VKAs) with clopidogrel 
alone. None patient received edoxaban. All patients were followed as part of routine 
clinical practice at each participating hospital for 1 year as previously described 
[16 ].
 
 
End-points and definitions 
 The primary end-point was defined as the occurrence of any degree of bleeding 
(major and minor) during follow-up according to the BARC (Bleeding Academic 
Research Consortium)
 
classification[17] (major bleeding defined as any bleeding event 
BARC ≥3a)[17]. We also analyzed any bleeding (BARC 1 & 2). The composite 
secondary end-point was the occurrence of any MACE, defined as death from any 
cause, myocardial infarction, target vessel revascularization or stent thrombosis, and 
death from any individual component cause [16]. 
 The two cohort studies complied with the Declaration of Helsinki and were 
approved by the Institutional Review Boards of all hospitals involved.  
 
Statistical analysis  
 Continuous variables are described as mean±standard deviation (SD) and range, 
and categorical variables as absolute and relative frequencies of patients in each 
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category. Comparison of continuous variables between the two treatment groups was 
made by Student's t-test and comparison for categorical variables by the chi-square test.  
 The propensity score (PS) (representing the probability of an individual patient 
receiving a DES) was computed using extensive non-parsimonious, logistic regression 
modeling with the several covariates. (Table 1).A PS matched-paired analysis was 
undertaken by estimation of the standardized difference between baseline characteristics in 
DES and BMS patients to assess the imbalance in covariates[18]. Each DES subject was 
matched to the closest available BMS subject using the estimated propensity score and a 
greedy-matching algorithm.  
 Survival analyses were conducted using a Kaplan–Meier method and compared 
using the log-rank test. In addition, we performed a Cox proportional hazard model 
analysis, considering the outcomes of total bleeding, major bleeding, MACE and all-
cause mortality to adjust the effect of clinical variables and the PS on outcome end-
points. To further ascertain whether the covariates had been successfully balanced using 
PS matching and to control for residual confounding, we then fitted these models with 
additional covariates, including potentially imbalanced demographic, clinical, cohort or 
procedural variables (i.e. P≤0.15 for comparison of means) [18]. All P-values were two-
sided and a P<0.05 were considered statistically significant. Statistical analyses were 
performed using the statistical package SPSS 23.0. 
RESULTS 
Baseline and procedural characteristics 
 One thousand and two patients requiring OAC were studied (mean age: 72±10 
years, male 72%).  Of these, 389 (38.8%) were treated with DES (first generation 
paclitaxel or sirolimus stents 35.2%; second generation DES in 32.5%; third generation 
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DES in 32.3%) and 613 (61.2%) with BMS. Baseline and procedural characteristics are 
summarized in Table 1.  
DES patients were more commonly diabetic with a history of stroke, PCI and 
previous MI.  The main indication for OAC was AF in both groups but this was more 
frequent in patients with DES (n=842, 84%; DES vs BMS: 81.2% vs 85.8%, P=0.01) 
(Table 1). In patients with AF, the proportion with CHA2DS2-VASc score ≥2 was not 
significantly different between both stent groups; however, a HAS-BLED score ≥3 was 
less prevalent in DES patients. 
 An acute coronary syndrome as index event was more common in DES patients. 
Although there were no differences in lesion type, DES patients had a higher number of 
diseased vessels and received a greater number of stents than those treated with BMS. 
 A PS matched analysis of 368 pairs was performed (Supplementary Table 1).  
Antithrombotic therapy 
 There were no significant differences in periprocedural antithrombotic treatment 
(low-molecular-weight or unfractionated heparin, glycoprotein IIb/IIIa receptor 
antagonists or level of OAC) between groups. Antithrombotic medications at discharge 
are presented in Table 1. The use of OAC was similar in both DES and BMS groups 
(56.8% vs 51.4%, P=0.29) as well as the use of TT (51.5% vs 50.9% respectively, both 
P=0.52). There was a non-significant trend towards a lower use of OAC plus 
clopidogrel in DES patients. The use of direct anticoagulants (DOACs) was low in our 
cohort (2% vs 2%) and in combination to DAPT. The mean duration of each 
antithrombotic strategy was substantially longer in the DES group (TT, 6.2±3 vs. 
1.5±0.5 months; OAC plus clopidogrel, 6.9±2.2 vs. 1.6±1 months; all P<0.0001). 
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Drug-eluting stents and bleeding events 
 Follow-up was complete in 98.8% of patients. No differences were observed in 
total and major bleeding events between cohorts (A: 2003-2006, B: 2007-2014; 15.2% 
vs 12.7%, P=0.15; 5.8% vs 6.2%, P=0.45, respectively). In the overall cohort, patients 
with BMS and DES suffered similar rates of total, major and minor bleeding (Table 2). 
The incidence of major bleeding events (BARC≥3) in patients on OAC was similar in 
patients with DES compared with BMS (8.9% vs 8.6%, p=0.52). Likewise, the 
incidence of bleeding events in patients receiving TT was similar (total: 16.5% vs 
16.7%, P=0.52; major 7.3% vs 7.6%, P=0.51; minor 7.9% vs 10.6%, P=0.18). Five 
DES and four BMS patients suffered fatal intracranial bleeds. Fifteen major bleeding 
events occurred during the index hospitalization (related to femoral access in 45% of 
cases). Early bleeding was more common in BMS patients, (within 30 days of 
procedure 38% vs 17%, p <0.0001). Bleeding tended to occur later in DES patients 
treated with TT (median 40 [range 1-201] days post procedure vs. 25 [range 1-40] days 
post procedure in BMS patients (P=0.01). 
 Kaplan–Meier survival curves demonstrated a similar incidence of total and 
major bleeding events at 1-year follow-up, regardless of stent type (Figures 1A, 1B).  
Multivariate analysis after adjustment for confounding variables demonstrated that DES 
use was not associated with the incidence of total or major bleeding (Table 3). 
Drug-eluting stents and major adverse cardiac events 
 Throughout follow-up, all-cause mortality and rates of MACE and stent 
thrombosis were similar in BMS and DES patients (Table 2). Twenty four patients 
(2.20%) suffered definite or probable stent thrombosis (DES 2.20% vs BMS 2.30%, 
P=0.54). Early stent thrombosis occurred in 6 patients (3 of each stent type) and late 
stent thrombosis in a further 18 (BMS n=8, DES n=10 [paclitaxel-eluting stent n=6, 
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third generation DES n=4]).  No patient suffered very late stent thrombosis. However 
the incidence of TVR was lower in DES patients (5.3% vs 8.5%, adjusted HR.0.52; 
95% CI: 0.29-0.92, P=0.02). 
 Kaplan-Meier survival curves demonstrated a similar incidence of MACE and 
all-cause of mortality at 1-year follow-up, regardless of stent type (Figures 1C and 1D, 
respectively). Multivariate analysis after adjustment for confounding variables 
demonstrated that DES use was not associated with MACE or all-cause mortality (Table 
3).  
 Additional data concerning outcome predictors identified using multivariate 
analysis are shown in Supplementary Table 2.  After adjusting for confounder variables, 
the use of DES was not associated to any adverse outcomes analyzed total and major 
bleeding, MACE or any cause of death.  
Secondary analysis. Safety of DES in patients at high risk of bleeding 
 Several subgroup analyses were performed. After adjustment, the association of 
DES with risk of 1-year total or major bleeding was similar between older (≥75 years) 
versus younger patients, men versus women, renal failure vs normal renal function, 
femoral access vs radial access (p for interaction >0. 05 f or al l ). Figure 2. 
Propensity score analysis 
 Stent type had no significant effect on outcome in the 368 propensity matched 
pairs (Table 2). Logistic regression identified  several variables as independent ‘risk 
factors’ for adverse outcomes (Table 3): female sex, age, stroke, diabetes, smoking, 
hypertension, hypercholesterolemia, previous PCI, previous CABG, previous MI, acute 
coronary syndromes, femoral access, number of vessels, total stent length, number of 
stents and antithrombotic therapy.  Multivariable analysis after adjustment for 
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confounding variables demonstrated that DES use was not significantly associated with 
adverse outcomes (total or major bleeding, MACE or all-cause mortality, Table 3). 
DISCUSSION 
 We found that DES use was not associated with a higher rate of bleeding when 
compared with BMS, despite longer duration of combined antithrombotic treatment, 
thereby reinforcing the notion that DES use is safe in patients who require long-term 
OAC. In addition, DES patients demonstrated similar rates of MACE and stent 
thrombosis. However, TVR and restenosis rates were lower in this group (despite higher 
prevalence of diabetes, previous PCI-S, CABG, and complex lesions)
[7,8]
.   Finally, DES 
use was not significantly associated with adverse outcomes in the propensity matched 
analysis. 
This prospective cohort of patients requiring long-term OAC reflects everyday 
clinical practice in OAC patients receiving DES. Importantly, this was not a randomised 
controlled trial and the similar rates of bleeding and ischemic events in DES and BMS 
patients may be readily explained by the good clinical judgement of the PCI operators 
concerning the choice of stent (DES vs BMS) and antithrombotic regime (TT vs DAT) 
in individual patients.  
The major concern of clinicians is the incidence of bleeding events in patients on 
OAC undergoing PCI-S. However, a short use of DAPT or DAT in this population 
recommended in the updated ESC guidelines could decrease these outcomes. The newer 
generation of DES has provided the use of shorter antithrombotic regimen in this 
scenario.   
Consistent with our findings, other authors found no significant difference 
between DES and BMS patients in the rates of major bleeding and thrombotic 
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complications[14,15,17]. Conversely, other authors concluded that routine DES use was 
inappropriate in this population due to increased risk of bleeding[13,19], even though 
longer regimes of TT in patients receiving first generation DES may have contributed to 
this difference.  
In addition, in our study the incidence of major bleeding events (BARC≥3) was 
a little lower than in a recent randomized trial-LEADERS-FREE study- (5.9% vs 6.0% 
compared to 7.2% vs 7.3% in the later study) [20]. Remarkably, in our study, 51% of 
patients were on TT with a mean duration of 6.2±3 in DES compared to BMS. 1.5±0.5 
months. In contrast, the ZEUS trial, which only included 12.% of patients on OAC, 
showed a surprisingly lower incidence of bleeding events (BARC≥3 was <1%)[21]. 
 Bleeding rates peaked in our study in the second month of treatment, in contrast 
with previous studies when bleeding events were most common during the first 30 days 
following PCI-S (and particularly during the index admission, perhaps as a result of 
more frequent use of femoral access). Higher rates of radial access (57.8%) in our study 
[12-14] may also explain this disparity. Furthermore, we tested for interactions among 
multiple subgroups and found no evidence of any of DES with bleeding events.  
          Consistent with previous reports, the use of TT in DES patients was low in our 
series, although similar to other series -for both DES and BMS- which may have 
resulted in a lower than expected incidence of major bleeding[12-16,23-25]. Moreover, 
although there is evidence to support a strategy of OAC combined with clopidogrel in 
this seting[26,27], this regime was infrequent in our series with a high number of ACS 
as  an index event. This was probably due to concerns that omission of DAPT could 
result in a higher incidence of early and late stent thrombosis. The number of patients 
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receiving this treatment combination was too insufficient to allow definitive 
conclusions.  
Our study confirms that restricted duration of TT in DES patients with AF is not 
associated with higher rates of stent thrombosis. Indeed, stent thrombosis seems to be 
rare in patients requiring OAC in real-world practice[12]. Moreover, risks of stent 
thrombosis are even lower with contemporary third generation and polymer-free 
DES[28],
 
and shorter durations of combination antithrombotic therapy might soon 
become routine clinical practice[29].   
 To this respect, our data is similar to that shown in the LEADERS-FREE trial 
where drug coated stents were used [29]. Hence, in LEADERS FREE,  stent thrombosis 
rate was 2.0% in patients with DES compared to 2.2% in those with BMS, while in our 
study this rate was 2.2% compared to 2.3% in BMS, despite including patients treated 
with first-generation stents. However, in the ZEUS trial the incidence of definite or 
probable stent thrombosis was lower than in our series (1.0% compared to 2.0% in 
patients with BMS), showing the role of hydrophilic polymer based stent, although 
patients on only OAC were 12.0% of the sample size[30]. 
On the other hand, DES reduces the rate of TVR compared with BMS[7,8] and 
in our series the TVR rate was significantly lower in patients treated with DES, with 
similar rates shown in LEADERS-FREE (5.4% vs 8.4% compared with 10.3% vs 5.6% 
in the later study) [29]. 
Furthermore, other antihrombotic options could be considered. AF is known to 
induce P-selectin levels, and thereby, platelet activation during AF. This might be of 
particular in AF patients undergoing PCI [31]. In addition, FXa is known to influence 
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cardiac cells via PAR1/PAR2 activation. Thus, FXa inhibition by inhibitors or PAR1 
inhibition by Vorapaxar might be effective in this clinical setting [32].  
Strengths and limitations  
 Our series included a large study population of 1,002 patients across the wide 
demographic and socio-economic spectrum with access to medical care.  
 Although the PS allows adjustment for differences in baseline characteristics and 
risk-based decision-making regarding treatment strategy, unmeasured confounders may 
compromise these comparisons. Furthermore, changes in antithrombotic regimens may 
have occurred during follow-up in relation to thrombotic or hemorrhagic complications. 
Reflecting on real world clinical practice, full information concerning the adequacy of 
anticoagulant control was unavailable which may have impacted on the risk of stroke 
and major hemorrhage. The use of DOACs was limited during this study, and we cannot 
draw conclusions. In our study none patient received Edoxaban, and we are waiting for 
the results of  ENTRUST AF-PCI study that it is on going (NCT02866175).   Finally, 
decisions concerning the choice of stent type and therapeutic regime at discharge were 
made at the discretion of the attending interventional cardiologist or clinician.  
Conclusions 
Our results suggest that DES use in patients requiring OAC is safe and reduces 
the incidence of ischaemic events in patients at high risk of restenosis. Until more 
randomized trial data is available on this population, selection of stent type should be 
based on assessment of individual patient characteristics, balancing the risks of bleeding 
and thromboembolism against the likelihood of stent thrombosis and restenosis. 
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Legends 
Figure 1. Kaplan–Meier survival curves relating to the use of drug-eluting stents (DES) 
and bare metal stents (BMS) in patients receiving triple therapy (TT). Number of 
patients followed up: BMS n=316; DES n=198. A. Total bleeding events; B. Major 
bleeding events; C. Major adverse cardiac events; D. All-cause mortality  
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Table 1. Baseline clinical and procedural characteristics of the study population 
 
BMS              
(N=613) 
DES                
(N=389) 
Difference 
(BMS vs 
DES)  
p value 
Women, n (%) 143 (23.3) 94 (24.1) 1.53 0.76 
Mean (SD), age (years) 72.3 (9.8) 71.5 (9.6) -8.25 0.22 
Medical history     
Indication for OAC, n (%)     
  Atrial fibrillation 526 (81.2)      316 (85.3) -20.2 0.01 
  Mechanical valve prosthesis 35 (5.7)          32 (8.2)   
  pulmonary embolism             18 (4.9)           8 (2.0)   
  *Other  33 (5.4)         12 (3.0)   
Smoking, n (%) 309 (50.4) 191 (49.1) -2.12 0.68 
Hypertension, n (%) 447 (72.9) 279 (71.7) -2.18 0.67 
Diabetes, n (%) 193 (31.4) 166 (42.6) 18.87 <0.0001 
Hypercholesterolaemia, n (%) 322 (52.5) 211 (54.2) 2.78 0.59 
History of heart failure, n  (%)    128 (21.2) 90 (23.4) 4.29 0.42 
History of stroke, n (%) 92 (15.0) 37 (9.5) -14.21 0.01 
Renal failure, n (%) 88 (14.3) 53 (13.6) -1.66 0.74 
Peripheral arterial disease, n (%) 71 (11.5) 49 (12.6) 2.74 0.63 
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Previous PCI, n (%) 153 (24.9) 137 (35.2) 18.16 <0.0001 
Previous CABG, n (%) 60 (9.8) 47 (12.1) 5.93 0.24 
Previous MI, n (%) 176 (28.7) 150 (38.5) 16.83 0.001 
HAS-BLED score ≥3, n (%) 424 (69.1) 249 (64.0) -8.78 0.09 
CHA2DS2-VASc score ≥ 2, n (%) 393 (64.2) 269 (69.4) 6.7 0.07 
ACS index event, n (%) 457 (77.2) 234 (65.4) 21.27 <0.0001 
Procedural characteristics     
Femoral access 326 (53.3) 165 (42.4) 20.56 0.001 
Mean (SD) total nº stents,  1.48 (0.8) 1.72 (0.9) 26.47 <0.0001 
Mean (SD) stent diameter, (mm)  3.5 (0.4) 3.2 (0.5) -1.91 0.05 
Mean (SD) stent length, (mm) 18 (23.0) 27 (14.0) 13.27 <0.0001 
Antithrombotic therapy     
Triple therapy, n (%) 316 (51.5) 198 (50.9) -0.98 0.52 
Dual antiplatelet therapy, n (%) 254 (41.4) 170 (43.7) 3.79  
Acenocumarol + clopidogrel, n (%) 43 (7.0) 21 (5.4) -5.35  
Mean (SD), duration of triple 
therapy, (months) 
1.5 (1.0) 6.2 (3.0) -5.2 0.0001 
Mean (SD), duration of dual 
antiplatelet, (months) 
1.6 (1.5)  7.3 (4.6) -4.2 0.0001 
 
Mean (SD), duration of 
acenocumarol + clopidogrel, 
(months) 
 
 1.6 (1.0) 
 
6.9 (2.2) 
 
       -4.9 
 
0.0001 
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Footnotes: MI: myocardial infarction; PCI: percutaneous coronary intervention; HAS-
BLED score: hypertension, renal/liver failure, stroke, bleeding history of predisposition, 
INR lability, age > 65 years, concomitant drugs or alcohol; ACS: acute coronary 
syndrome as the indicator for PCI. *Other indications for OAC: left ventricular 
thrombus, mitral stenosis, ventricular dysfunction, or antiphospholipid syndrome 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
29 
 
Table 2. Comparison of outcomes between stent groups before and after propensity score matching over 1-year follow-up 
 Before propensity score After propensity score 
 
BMS          
(N=613) 
DES     
(N=389) 
P value 
BMS 
(N=368) 
DES 
(N=368) 
p value 
Total bleeding (%) 
82 (13.4) 56 (14.4) 0.64 42 (11.4) 54 (14.6) 0.18 
Major bleeding (%) 
         37 ( 6.0) 23 (5.9) 0.93 19 ( 5.1) 23 (6.2) 0.52 
Minor bleeding (%) 
         38 ( 6.2) 32 (8.2) 0.22 23 (6.2) 30 (8.1) 0.31 
MACE (%) 
114 (18.6) 59 (15.2) 0.09 67 (18.3) 67 (18.2) 0.46 
All-cause mortality (%) 
71 (11.5) 42 (10.8) 0.70 37 (10.0) 41 (11.1) 0.63 
Cardiovascular mortality (%) 
49 ( 7.9) 26 ( 6.6) 0.44 26 ( 7.0) 25 ( 6.7) 0.88 
Target vessel revascularization 
52 ( 8.5) 21 ( 5.4) 0.02 32 ( 8.7) 25 ( 6.7) 0.33 
Stent thrombosis (%) 
11 (1.8) 7 ( 1.8) 0.98 7 (1.9) 8   ( 2.1) 0.85 
MAE (%) 
166 (27.0) 107 (27.5) 0.88 97 (26.3) 104 (28.2) 0.56 
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Footnotes: MACE: major adverse cardiac events (death, myocardial infarction, target vessel failure or stent thrombosis), MAE: major adverse 
events (MACE, any thromboembolic or major bleeding event).   
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Table 3. Cumulative incidence of outcome events for the whole population and by stent type, and association between DES and 
outcome events 
 Cumulative incidence   HR (95% CI)  
 
 
BMS 
N=613 
 
DES 
N=389 
P 
 
Unadjusted 
N=1002 
 
P 
 
*Cox regression 
Adjusted 
N=1002 
 
P 
 
**PS paired 
N=750 
P 
 
    
 
 
 
 
 
Total bleeding 
(model 1) 
      82 (13.4)      56 (14.4)                     0.64 0.82 (0.58-1.14) 0.82 0.82 (0.58-1.17) 0.37 1.17 (0.75-1.85) 0.47 
Major bleeding 
(model 2) 
     37 ( 6.0)      23 ( 5.9)   0.93 0.94 (0.56-1.59) 0.84     1.22 (0.71-2.09) 0.46 0.86 (0.41-1.81) 0.69 
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           Footnotes: *Model 1:  adjusted for: age, stroke, CABG, antithrombotic therapy, HAS-BLED score. 
*Model 2: adjusted for: sex, age, stroke, HAS-BLED score, acute coronary syndrome, antithrombotic therapy. 
*Model 3: adjusted for: sex, age, smoking, hypertension, CABG, heart failure, acute coronary syndrome, number of vessels, 
antithrombotic therapy. 
*Model 4: adjusted for: age, smoking, hypertension, diabetes, CABG, heart failure, acute coronary syndrome, number of vessels, 
antithrombotic therapy. 
**PS: sex, age, stroke, diabetes, smoking, hypertension, hypercholesterolemia, previous PCI, previous CABG, previous MI, acute 
coronary syndrome, number of vessels, number of stents, antithrombotic therapy.  
MACE  
(model 3)   
 97 (15.8)  52 (13.3) 0.28 0.82 (0.58-1.14) 0.25 0.82 (0.57-1.17) 0.28 0.79 (0.52-1.18) 0.26 
All-cause death 
(model 4) 
       42 (10.8)      71 (11.5)   0.70 0.92 (0.63-1.35) 0.99 1.09 (0.71-1.65) 0.94 1.02 (0.88-1.19) 0.67 
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